The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients

AIM: Despite promising preclinical findings regarding clinical utility of farnesyltransferase inhibitors (FTI), such as lonafarnib, success of clinical trials is limited. A multicentre AGO-OVAR-15 phase II trial reported an unfavourable effect of lonafarnib on the outcome of patients with advanced o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Clin Pharmacol
Asıl Yazarlar: Bachmann, Hagen Sjard, Meier, Werner, du Bois, Andreas, Kimmig, Rainer, Kuhlmann, Jan Dominik, Siffert, Winfried, Sehouli, Jalid, Wollschlaeger, Kerstin, Huober, Jens, Hillemanns, Peter, Burges, Alexander, Schmalfeldt, Barbara, Aminossadati, Behnaz, Wimberger, Pauline
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2015
Konular:
Pharmacogenetics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631186/
https://ncbi.nlm.nih.gov/pubmed/26033044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12688
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller